ALPPS for Patients with Colorectal Liver Metastases: Effective Liver Hypertrophy, but Early Tumor Recurrence

• DOI: 10.1007/s00268-013-2401-2
• Publication Date: 2013-12-10T18:23:24Z
• Authors: Karl J. Oldhafer; Marcello Donati; Robert M. Jenner; Axel Stang; Gregor A. Stavrou
• Keywords: Carcinoembryonic antigen; Cardiothoracic surgery; Colorectal Surgery

AbstractBackgroundAssociating liver partition and portal vein ligation for staged hepatectomy (ALPPS) is a promising method to increase resectability rates of liver tumors. Little has been published about oncological results so far. This report describes clinical evidence regarding a possible effect of ALPPS on tumor recurrence.MethodsTen ALPPS procedures were performed for otherwise non‐resectable colorectal liver metastases. Seven of these ten patients had a follow‐up of at least 3 months and were analyzed for tumor recurrence.ResultsSix of these seven patients had tumor recurrence to the liver. Three of seven patients presented with lung metastases, occurring earlier than liver metastases in two of three cases. One patient with a follow‐up of 3 months had no visible recurrent disease, but increasing carcinoembryonic antigen levels.ConclusionsThe patient group operable only through ALPPS is at high risk for recurrence and early tumor progression. Still, this new method is the only chance for an oncological treatment strategy including a surgical approach and possibly better outcome.